Know Cancer

forgot password

Effectiveness of the FairCare System for Patients With Advanced Illness

Phase 2
18 Years
Not Enrolling
Terminal Care, Neoplasm

Thank you

Trial Information

Effectiveness of the FairCare System for Patients With Advanced Illness


This study of the FairCare Program (FC) is designed to address end of life (EOL) care
delivery issues by reducing barriers to effective EOL care among health care providers,
family members, surrogates, and Chronic Heart Failure (CHF) patients using a comprehensive,
multi-pronged approach delivered by a care coordinator and supported by an interdisciplinary


Evaluate the impact of FC on: 1) improving the quality of life (QOL) and health care
delivery for CHF patients with advanced illness, (i.e. ejection fractions of 35% or less, or
assessed as level III or IV on the NYS Heart Association Classification System); 2)
addressing their fears about dying; 3) increasing their use of Advance Directives (ADs); and
4) improving provider compliance with ADs. Also, describe trends that may occur in
disease-specific QOL, survival, and health care use and cost.


The study employs a randomized control group design. There are two treatment arms, the FC
treatment condition, and the usual care (UC) control condition. Assessments for improving
quality of life (QOL), and quality of care delivery are taken at baseline, and at three and
six months. Assessments of AD use, i.e. frequency of formulation and documentation of ADs,
are taken at baseline, three and six months at one year and 18 months. Because data about
compliance with ADs and utilization and cost may not be fully comprehensive until patients'
deaths, to maximize the sample size for these variables, and hence the power of the study to
detect difference in these outcomes, data on compliance with ADs will be collected in the
final year of the study, and data on utilization and cost will be aggregated in monthly
intervals and collected from baseline to 18 months. One year of VA pre-intervention health
care utilization and cost data will also be collected to assess baseline utilization and to
control for any pre-existing differences in the propensity of patients to use health care
services. Also, an intention to treat methodology will be used during data analyses.


The study ends 9-30-04, data for VA cost, Medicare cost, consistency of medical care with
patient preferences, and survival, are being collected and analyzed for the final report.

Inclusion Criteria:

Ejection fraction 35% or less and classification at level 3 or 4 of the New York State
Heart Classification System and surrogates of patients meeting this criteria.

Exclusion Criteria:

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Principal Investigator

Mollie Shulan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Albany VA Medical Center: Samuel S. Stratton


United States: Federal Government

Study ID:

CHI 99-071



Start Date:

Completion Date:

September 2004

Related Keywords:

  • Terminal Care
  • Neoplasm
  • Neoplasms



Albany VA Medical Center: Samuel S. Stratton Albany, New York  12208